文献速递重症综合管理与镇静镇痛复苏、休克与脓毒症

重症监护与出院后新起始米多君治疗的延续:单中心回顾性研究

Continuation of Newly Initiated Midodrine Therapy After Intensive Care and Hospital Discharge: A Single-Center Retrospective Study.
PubMed 文献 · Crit Care Med · 2019-01-01
一句话结论单中心回顾性研究显示,ICU出院时67%、医院出院时34%的患者继续使用新起始的米多君,其风险与获益尚不明确。

该单中心回顾性研究纳入2011年1月至2016年10月在Mayo Clinic Rochester各ICU因低血压新起始米多君并存活至出院的成人患者。ICU出院时67%(672/1,010)继续使用米多君,医院出院时34%(311/909)继续使用。心血管外科ICU及混合内外科ICU入住是ICU出院时继续用药的危险因素,充血性心力衰竭病史预测医院出院时继续用药。ICU出院时使用米多君与更短ICU住院时间及更低院内死亡风险相关,但医院出院时使用米多君与更高1年死亡风险相关。作者认为该实践的风险与获益仍不明确,未来研究应探索其对患者结局和资源利用的影响。

要点

  • ICU出院时67%(672/1,010)患者继续使用新起始的米多君,医院出院时34%(311/909)继续使用。
  • 心血管外科ICU入住(OR 3.94,95%CI 2.50-6.21)和混合内外科ICU入住(OR 2.03,95%CI 1.29-3.20)是ICU出院时继续米多君的危险因素。
  • 充血性心力衰竭病史预测医院出院时继续米多君(OR 1.49,95%CI 1.05-2.12)。
  • ICU出院时使用米多君与更短ICU住院时间(7.5±8.9 vs 10.6±13.4天)及更低院内死亡风险相关(HR 0.47,95%CI 0.32-0.70,p<0.001)。
  • 医院出院时使用米多君与更高1年死亡风险相关(HR 1.60,95%CI 1.26-2.04,p<0.001)。

适用人群与场景

  • 2011年1月至2016年10月在Mayo Clinic Rochester任何ICU因低血压新起始米多君并存活至出院的成人患者。

研究设计与关键结果

  • 单中心回顾性研究,纳入1,010例新起始米多君并存活至ICU出院的成人ICU患者。
  • ICU出院时67%(672/1,010)继续使用米多君;医院出院时34%(311/909)继续使用米多君。
  • 心血管外科ICU入住(OR 3.94,95%CI 2.50-6.21)和混合内外科ICU入住(OR 2.03,95%CI 1.29-3.20)是ICU出院时继续米多君的危险因素。
  • 充血性心力衰竭病史预测医院出院时继续米多君(OR 1.49,95%CI 1.05-2.12)。
  • 高血压和机械通气与ICU及医院出院时米多君处方几率降低相关。
  • 在ICU或医院出院时使用米多君的患者中,50%同时处方了降压药。
  • ICU出院时使用米多君与更短ICU住院时间(7.5±8.9 vs 10.6±13.4天)及更低院内死亡风险相关(HR 0.47,95%CI 0.32-0.70,p<0.001),尽管基线疾病严重程度评分无差异。
  • 医院出院时使用米多君与更高1年死亡风险相关(HR 1.60,95%CI 1.26-2.04,p<0.001)。

证据类型、等级与局限

  • 证据类型:单中心回顾性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 该研究提示ICU及医院出院时新起始米多君延续使用常见,作者认为其风险与获益仍不明确,未来研究应探索该实践对患者结局和资源利用的影响,并可用于建模规范减量、停药或随访的干预措施。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: Midodrine is an α1-agonist approved for orthostatic hypotension. Recently, it has received attention as an oral vasopressor to facilitate ICU discharge. The purpose of this study was to identify the incidence of continuation of newly initiated midodrine upon ICU and hospital discharge and identify risk factors associated with its occurrence.

DESIGN: Single-center retrospective study.

SETTING: ICU patients from January 2011 to October 2016 at Mayo Clinic, Rochester.

PATIENTS: Adult patients admitted to any ICU who received new midodrine for hypotension and survived to discharge.

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: During the study period, 1,010 patients were newly started on midodrine and survived to ICU discharge. Midodrine was continued in 67% (672/1,010) of patients at ICU discharge. Admission to cardiovascular surgery ICU and mixed medical/surgical ICU was a risk factor for midodrine continuation at ICU discharge (odds ratio, 3.94 [2.50-6.21] and 2.03 [1.29-3.20], respectively). At hospital discharge, 34% (311/909) of patients were continued on midodrine therapy. History of congestive heart failure predicted midodrine continuation at hospital discharge (odds ratio, 1.49 [1.05-2.12]). Hypertension and use of mechanical ventilation were associated with a decreased odds of midodrine prescription at both ICU and hospital discharge. Of those discharged from the ICU or hospital on midodrine, 50% were concomitantly prescribed antihypertensives. Discharge from the ICU on midodrine was associated with a significantly shorter ICU length of stay (7.5 ± 8.9 vs 10.6 ± 13.4 d) and reduced risk of in-hospital mortality (hazard ratio, 0.47 [95% CI, 0.32-0.70]; p < 0.001), despite no difference in baseline severity of illness scores. In contrast, patients discharged from the hospital on midodrine had a higher risk of 1-year mortality (hazard ratio, 1.60 [95% CI, 1.26-2.04]; p < 0.001).

CONCLUSIONS: This study established a high prevalence of midodrine continuation in transitions of care. The risks and benefits of this practice remain unclear. Future studies should explore the impact of this practice on patient outcomes and resource utilization. These insights could be used to model interventions for proper tapering, discontinuation, or follow-up of new start midodrine.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Rizvi MS, Nei AM, Gajic O, et al. Continuation of Newly Initiated Midodrine Therapy After Intensive Care and Hospital Discharge: A Single-Center Retrospective Study. Crit Care Med. 2019. PMID: 31107279. doi:10.1097/CCM.0000000000003814

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。